Current EB treatments in the UK
As one of the largest investors in EB research globally, DEBRA UK funds pioneering research that aims to find effective treatments for all types of inherited EB. This includes our drug repurposing programme, which is the technique of using an existing drug for a new treatment or medical condition that it was not originally intended for.
There are also other organisations working on developing EB treatments. This page is where we will share information about all new EB treatments as they become available for use in the UK.
Available EB treatments in the UK
Filsuvez®, the gel developed by Amryt Pharma as a treatment to promote the healing of partial thickness wounds associated with dystrophic EB (DEB) and junctional EB (JEB), has been approved for use in the UK by the National Institute for Health Care and Excellence (NICE).
Filsuvez® is available via prescription for UK DEB and JEB patients aged 6 months+ through the NHS EB specialist centres.
Please contact your EB specialist healthcare team for advice on accessing Filsuvez®, and to find out if you could benefit from it. If you aren’t already under the care of an EB specialist healthcare team, our website has information on how to be referred.
You can also learn more in our Filsuvez® FAQs.